The Assessment of Prednisone In Remission Trial - Centers of Excellence Approach
Status:
Recruiting
Trial end date:
2022-12-01
Target enrollment:
Participant gender:
Summary
This study is a multi-center randomized controlled trial to evaluate the effects of using
low-dose prednisone as compared to stopping prednisone treatment entirely. Participants will
be randomized 1:1 to taper their prednisone dose down to 5 mg/day or to 0 mg/day for the
duration of the study (approximately six months) or until a study endpoint.
Phase:
Phase 3
Details
Lead Sponsor:
University of Pennsylvania
Collaborators:
National Center for Advancing Translational Science (NCATS) National Heart, Lung, and Blood Institute (NHLBI) National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) Office of Rare Diseases (ORD) Rare Diseases Clinical Research Network